TargetBeta
C3
complement C3 · also CPAMD1, ARMD9, C3a, C3b · Receptor ligands
2 programs in company-led studies act on C3, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| pegcetacoplanrule | Biogen | inhibitor | phase 4 | 307 running | – | NCIt |
| SSS55rule | 3SBio | – | phase 1 | 11 running | – | the studies' text |
Conditions their studies are in
- Anemia, Hemolytic, Autoimmune, 1 program
- Geographic Atrophy, 1 program
- Glomerulonephritis, Membranoproliferative, 1 program
- Hemoglobinuria, Paroxysmal, 1 program
- Macular Degeneration, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026SSS55 · 3SBio · phase 1 · NCT07058779
- Jun 25, 2027pegcetacoplan · Biogen · phase 4 · NCT07215390
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.